Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/01/2022* -- Results Q4 2022 -- 0.63 --
11/01/2022* 16:30 EST Earnings Call Q4 2022 -- -- --
07/27/2022 16:30 EST Earnings Call Q3 2022 -- -- --
07/27/2022 -- Results Q3 2022 0.95 0.70 35.74%
04/27/2022 -- Results Q2 2022 2.07 1.60 28.97%
04/27/2022 16:30 EST Earnings Call Q2 2022 -- -- --
02/02/2022 -- Results Q1 2022 2.17 1.31 65.89%
02/02/2022 16:30 EST Earnings Call Q1 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/01/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/27/2022
Beat/Miss Upgrade
Return Since -11.22%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
URL http://www.hologic.com
Investor Relations URL https://investors.hologic.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Medical Instruments & Supplies
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 01, 2022 (est.)
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
44.69%
3.70%
6.56%
-3.86%
27.03%
39.49%
5.12%
-17.74%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.61%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
16.08%
13.97%
16.77%
24.56%
-7.55%
14.49%
21.51%
14.53%
-67.43%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-38.08%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-70.79%
As of September 23, 2022.

Profile

Edit
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
URL http://www.hologic.com
Investor Relations URL https://investors.hologic.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Medical Instruments & Supplies
Equity Style Mid Cap/Blend
Next Earnings Release Nov. 01, 2022 (est.)
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
UTRN 2.979M USD 4.01%
PARMX 253.55M USD 3.75%
PMEGX 148.58M USD 3.06%
DDVRX 218.56M USD 2.98%
FVUSA04AZ9 147.26M USD 2.98%
RRMGX 814.28M USD 2.97%
FXH 27.92M USD 1.97%
VSMV 1.868M USD 1.60%
IHI 93.52M USD 1.55%
XHE 5.574M USD 1.45%
THISX 217.16M USD 1.40%
QQQJ 10.25M USD 1.39%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter HOLX Tweets